naloxone intranasal

Phase 3Small molecule

NNorwegian University of Science and Technology

naloxone intranasal is one of 15 small molecule programs targeting Overdose. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OverdoseActive, not recruiting

OverdosePhase 3

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Overdose

#DrugCompanyPhaseTrials

Narcan

SScienture

Approved

2 2

Suboxone

IIndivior Inc.

Approved

—3

Ativan

BBausch Health Americas, Inc.

Phase 2

1 4

Haldol

DDePuy Orthopaedics

Phase 2

1 5

Cysteine Hydrochloride

Novartis

Phase 1

1 6

Acetadote

AArbor Pharmaceuticals, Inc.

Phase 1

1 7

naloxone intranasal

NNorwegian University of Science and Technology

Phase 3

1 8

Sublocade

IIndivior Inc.

Phase 3

1 9

Intravenous

IIsfahan University of Medical Sciences

Phase 2

1 10

MS Contin

Merck & Co.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pilot Study1 trial

A Pilot Study of the Bioavailability of Nasal Naloxone

Completed·NNorwegian University of Science and Technology·Phase 2·NCT01939444·5 enrolled

Overdose1 trial

Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital

Completed·NNorwegian University of Science and Technology·Phase 3·NCT03518021·286 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for naloxone intranasal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — naloxone intranasal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for naloxone intranasal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Norwegian University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNorwegian University of Science and Technology

naloxone intranasal

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pilot Study1 trial

Overdose1 trial

References

Drug Info

Quick Facts

Related News